Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program

Mathilde Lamarque1, Céline Bossard2, Adrien Contejean3

  • 1Institut IMAGINE, Unité INSERM U1163, Paris, France Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique - Hôpitaux de Paris, Créteil, France Unité INSERM U955, Créteil, France.

Haematologica
|December 26, 2015
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos